Operator

Good day, and welcome to the educational KOL webinar [Operator Instructions]. Please note, this event is being recorded.

I would now like to turn the conference over to Leah Gibson, Vice President of IR and Corporate Communications. Please go ahead.

Leah Gibson

Good morning, and thank you for joining our educational webinar to discuss the multiple myeloma landscape, including the role of IKZF1/3 degraders and the emerging profile of cemsidomide. We will be making forward-looking statements today, and Slide 2 contains our legal disclaimer on this matter. Those presenting on today's call are Andrew Hirsch, our President and CEO; and Nisha Joseph, Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine; and Len Reyno, our Chief Medical Officer.

Andrew will begin with opening remarks and then hand it over to Dr. Nisha Joseph, who will go over the multiple myeloma landscape and IKZF1/3 degraders Foundational biology. Len Reyno will discuss some cemsidomide's potential best-in-class profile. We will end today's call with a Q&A session. Andrew, over to you.

Andrew Hirsch
CEO, President & Director

Thank you, Leah, and good morning, everyone. Thank you for joining us. As you know, C4 Therapeutics is a leading clinical-stage biopharmaceutical company advancing the novel modality of targeted protein degradation to treat patients with cancer as well as inflammatory, neuroinflammatory and neurodegenerative diseases. Our lead asset, cemsidomide, is the next-generation IKZF1/3 degrader in development for relapsed/refractory multiple